Novavax, Inc. (NASDAQ:NVAX) – Stock analysts at B. Riley cut their Q3 2018 earnings estimates for shares of Novavax in a report released on Wednesday. B. Riley analyst M. Kumar now forecasts that the biopharmaceutical company will post earnings of ($0.16) per share for the quarter, down from their previous forecast of ($0.15). B. Riley currently has a “Buy” rating and a $10.00 target price on the stock. B. Riley also issued estimates for Novavax’s Q4 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.62) EPS, FY2019 earnings at ($0.76) EPS, FY2020 earnings at ($0.42) EPS, FY2021 earnings at $0.33 EPS and FY2022 earnings at $1.27 EPS.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.42 million. During the same quarter last year, the company posted ($0.24) EPS. Novavax’s revenue was up 158.5% on a year-over-year basis.

NVAX has been the subject of a number of other research reports. BidaskClub downgraded Novavax from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Zacks Investment Research downgraded Novavax from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Cantor Fitzgerald reiterated a “hold” rating and set a $2.00 price objective on shares of Novavax in a research report on Monday, December 18th. Citigroup upgraded Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Seaport Global Securities reiterated a “neutral” rating on shares of Novavax in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. Novavax currently has a consensus rating of “Hold” and a consensus price target of $3.68.

Shares of Novavax (NVAX) opened at $1.61 on Monday. Novavax has a 52-week low of $0.73 and a 52-week high of $2.14. The company has a market capitalization of $520.40, a price-to-earnings ratio of -2.37 and a beta of 2.03. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31.

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVAX. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Novavax by 49.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 29,800 shares in the last quarter. Profund Advisors LLC lifted its holdings in shares of Novavax by 0.4% in the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 455 shares in the last quarter. Voya Investment Management LLC lifted its holdings in shares of Novavax by 18.6% in the second quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 21,639 shares in the last quarter. Brown Advisory Inc. lifted its holdings in shares of Novavax by 74.8% in the third quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 69,600 shares in the last quarter. Finally, Federated Investors Inc. PA acquired a new position in shares of Novavax in the second quarter worth $232,000. Institutional investors own 35.69% of the company’s stock.

In other Novavax news, insider Stanley C. Erck bought 100,000 shares of Novavax stock in a transaction dated Thursday, November 9th. The stock was bought at an average price of $1.13 per share, for a total transaction of $113,000.00. Following the completion of the acquisition, the insider now directly owns 228,279 shares of the company’s stock, valued at $257,955.27. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.00% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/15/brokers-issue-forecasts-for-novavax-inc-s-q3-2018-earnings-nvax.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.